CN114452284B - Application of STING inhibitor in preparation of medicine for treating conjunctival scarring of filter - Google Patents
Application of STING inhibitor in preparation of medicine for treating conjunctival scarring of filter Download PDFInfo
- Publication number
- CN114452284B CN114452284B CN202210063512.7A CN202210063512A CN114452284B CN 114452284 B CN114452284 B CN 114452284B CN 202210063512 A CN202210063512 A CN 202210063512A CN 114452284 B CN114452284 B CN 114452284B
- Authority
- CN
- China
- Prior art keywords
- sting
- inhibitor
- filter
- scarring
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application of the STING inhibitor in preparing medicines for resisting the treatment of the conjunctival scarring of the filterable tract is found that H151 can inhibit the fibrosis, proliferation and migration capacity of HTF cells induced by angiotensin II, further inhibit the activation of TBK1 and IRF3 mediated by STING and the transcriptional activity of transcription factor NF- κB, so as to relieve the fibrosis of conjunctival sac of the filterable tract and the scarring of the filterable tract, and improve the long-term effective rate after glaucoma is small Liang Shu.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to application of STING inhibitors in preparation of medicines for treating conjunctival scarring of a filter passage.
Background
Glaucoma is a disease that causes irreversible optic nerve degeneration due to pathological changes in ocular tension, and is the first irreversible blinding eye disease worldwide. Glaucoma trabeculectomy is the most classical and widely used surgical procedure for treating various types of glaucoma, and can effectively reduce elevated intraocular pressure of glaucoma. According to previous studies, early trabeculectomy has been found to have an early surgical success rate as high as 83% to 92%, but this ratio gradually drops to 65% -44% during long follow-up.
The main cause of failure after trabeculectomy is scarring of the conjunctiva of the filter, resulting in a decrease in the effective filtering function after surgery and a renewed rise in ocular pressure. At present, the pathogenesis of scar formation after glaucoma trabeculectomy is still not completely clear, and the occurrence and development of scar formation in a filtration passage cannot be completely and effectively prevented only by adopting traditional means such as filtration, infusion and needle-stick separation, laser broken wire or subconjunctival injection of cell proliferation inhibiting medicaments. Therefore, the generation mechanism of the conjunctiva scarring of the filtering passage after the trabeculectomy is clarified, a new drug target is searched, the development of targeted therapeutic drugs is facilitated, and the method has important scientific significance and clinical application value.
H151 is a potent, selective and covalent STING antagonist with significant inflammatory inhibitory activity in vitro and in vivo. H151 has effects of anti-inflammatory, suppressing excessive immune reaction, relieving skin injury, protecting kidney and liver, etc.
However, no treatment of trabeculectomy followed by scar formation of the filtrate was reported for H-151.
Disclosure of Invention
In order to solve the technical defects in the prior art, the invention provides application of STING inhibitor in preparing medicines for treating conjunctival scarring of a filter path.
The conjunctival scarring of the filter tract is carried out after the glaucoma is small Liang Shu.
The STING inhibitor is a STING inhibitor H151.
The structure of STING inhibitor H151 is as follows:
。
the concentration of the STING inhibitor H151 is 1 mug/ml.
The application of TBK1, IRF3 and inhibitors of transcription factor NF- κB signal path in preparing medicine for treating conjunctival scarring of filter path.
The inhibitor of the TBK1, IRF3 and transcription factor NF- κB signal path is H151.
Use of STING inhibitor H151 for the preparation of a medicament for alleviating fibrosis, proliferation and migration of HTF cells.
The beneficial effects of the invention are as follows: the invention provides an application of STING inhibitor in preparing medicines for treating conjunctival scarring of a filter, and discovers that H151 can inhibit fibrosis, proliferation and migration capacity of HTF cells induced by angiotensin II, further inhibit activation of TBK1 and IRF3 mediated by STING and transcriptional activity of transcription factor NF- κB, so as to relieve conjunctival sac fibrosis of the filter and scarring of the filter, and improve long-term effective rate after glaucoma is small Liang Shu.
Drawings
Fig. 1 is a graph of H151 stabilized mouse bleb morphology following trabeculectomy and relief of post-operative filter fibrosis.
FIG. 2 is a graph of H151 inhibiting the fibrosis response induced by Ang II in HTF cells.
Fig. 3 h151 inhibits activation of the STING downstream signaling pathway.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by one of ordinary skill in the art without undue burden from the invention, are within the scope of the invention based on the embodiments of the invention.
Example 1
The trabeculectomy postfiltration tract scarring model is successfully constructed, the trabeculectomy operation mode of the mice is referred to the previous literature report (Invest Ophthalmol Vis Sci.2017, 58 (9): 3432-3439), the treatment is carried out by injecting the STING specific small molecule inhibitor H151 into conjunctival sac after the operation for 2 weeks, and the condition of conjunctival bleb of the mice is observed by photographing under an operation microscope after the anesthesia for 2 weeks.
The test process comprises the following steps: male C57BL/6 mice were purchased from commercial animal experiment centers. Mice were kept in animal houses with a constant circadian 12-12h rhythm with standard rodent diet and water. Animals were grown for environmental adaptation one week prior to the start of the experiment. The H151 used in the experiment was prepared as a DMSO-soluble dosage form at a final concentration of 1mg/kg. A trabeculectomy filter scar mouse model was established, and mice were sacrificed 2 weeks later under anesthesia using a sham operation as a control group. Sham is a Sham surgery group; surry is the trabeculectomy group; the surgery+h151 group is a trabeculectomy combined H151 treatment group. (A) Pre-sacrificed mice trabeculectomy filter bleb conditions after anesthesia; (B) trabeculectomy followed by filtration lane HE staining; (C, D) immunofluorescence detection of mouse trabeculectomy filter αsma expression levels; (E) Real time qPCR detects mRNA levels of fibrinectin and CTGF. * P < 0.01, < p < 0.001, sham vs. Surgery; # p < 0.01, # p < 0.001, surgery vs Surgery +h151.
The surgical group showed that the bleb was significantly limited and scarred under the surgical microscope, the bleb surface was hyperemic, and the surgical combination H151 treatment group showed that blebs formed well with a pale surface, see fig. 1A. To investigate the effect of H151 on the intervention of changes in trabeculectomy morphology and fibrosis, we used HE staining and alpha SMA immunofluorescence observations, respectively. As shown in fig. 1B-D, HE staining showed a significant increase in collagen deposition and αsma expression in the mouse filter following trabeculectomy, while there was a significant relief after H151 treatment. The RT-qPCR results showed a significant increase in the levels of fibractin and CTGF mRNA in the trabecular conjunctival tissue of mice receiving the trabecular surgery compared to the sham surgery group, while the H151 treated group was decreased as shown in fig. 1E, F.
Example 2
HTF cells were pre-incubated with H151 for 1H, and then HTF cells were stimulated with Ang II (1 μm) for 6 or 24H, using fluorescent staining, fluorescent quantitation, RT-qPCR, western Blot, and scratch experiments, respectively, to examine the effect of H151 on Ang II.
The test process comprises the following steps: h151 (final concentration 1. Mu.g/ml) pre-incubated HTF cells for 1 hour, ang II (1. Mu.M) stimulated 6 or 24 hours. (a, B) immunofluorescence detection of mouse trabeculectomy filter αsma expression levels; (C) Western Blot detects protein levels of fibractin and CTGF; (D, E) Real time qPCR to detect mRNA levels of fibreonectin and CTGF; (F) a migration scratch test to detect HTF cell migration ability; (G) CCK8 detects the proliferation potency of the cells. * P < 0.01, < p < 0.001, ctrl vs Ang II; # p < 0.01, # p < 0.001, ang II vs Ang ii+h151.
As shown in fig. 2a, b, H151 was found to inhibit Ang II-induced αsma expression by immunofluorescent staining. As can be seen in FIGS. 2C-E, the expression of the factor associated with Ang II induced pro-fibrosis, fibrinectin and CTGF, was increased at the protein and mRNA levels, whereas preincubation of H151 inhibited the expression of the factor associated with Ang II induced fibrosis. Meanwhile, the cell scratch experiment indicates that the migration of cells is obviously accelerated under the stimulation of Ang II, the migration acceleration of the pre-incubated H151 group is relieved (figure 2F), and H151 is observed to obviously inhibit the proliferation of HTF cells caused by Ang II in the cell proliferation experiment (figure 2G). The results show that the small molecule inhibitor H151 has better alleviation effect on HTF cell fibrosis, migration and proliferation caused by Ang II.
After 1 hour of pretreatment with H151, ang II was incubated for 2 hours, and changes in phosphorylation of the downstream signaling pathways TBK1, IRF3 and NF-. Kappa.B-p 65 were detected using Western Blot.
The test process comprises the following steps: h151 (final concentration 1. Mu.g/ml) pre-incubated HTF cells for 1 hour, ang II (1. Mu.M) was stimulated for 2h. Western Blot detects protein levels of p-TBK1, p-IRF3 and p-NF- κ B p 65.
As shown in FIG. 3, H151 significantly inhibited TBK1, IRF3 and NF-. Kappa.B-p 65 phosphorylation. Thus, the above results suggest that the effect of the small molecule inhibitor H151 on regulation of fibrosis is associated with TBK1, IRF3 and NF- κb signaling pathways.
The skilled person will know: while the invention has been described in terms of the foregoing embodiments, the inventive concepts are not limited to the invention, and any modifications that use the inventive concepts are intended to be within the scope of the appended claims.
The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above examples, and all technical solutions belonging to the concept of the present invention belong to the protection scope of the present invention. It should be noted that modifications and adaptations to the present invention may occur to one skilled in the art without departing from the principles of the present invention and are intended to be within the scope of the present invention.
Claims (6)
1. The application of STING inhibitor in preparing medicine for treating conjunctival scarring of filter is characterized in that the STING inhibitor is STING inhibitor H151.
2. The use according to claim 1, wherein the scarring of the conjunctiva of the bleb is performed after the glaucoma is small Liang Shu.
3. The use according to claim 1, wherein said STING inhibitor H151 has the structure:
。
4. the use according to claim 1, wherein said STING inhibitor H151 is present in a concentration of 1 μg/ml.
5. The application of the inhibitor of TBK1, IRF3 and transcription factor NF- κB signal path in preparing the medicine for treating conjunctival scarring of filter path is characterized in that the inhibitor of TBK1, IRF3 and transcription factor NF- κB signal path is H151.
6. Use of STING inhibitor H151 for the preparation of a medicament for alleviating fibrosis, proliferation and migration of HTF cells in vitro.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210063512.7A CN114452284B (en) | 2022-01-20 | 2022-01-20 | Application of STING inhibitor in preparation of medicine for treating conjunctival scarring of filter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210063512.7A CN114452284B (en) | 2022-01-20 | 2022-01-20 | Application of STING inhibitor in preparation of medicine for treating conjunctival scarring of filter |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114452284A CN114452284A (en) | 2022-05-10 |
CN114452284B true CN114452284B (en) | 2023-09-01 |
Family
ID=81409572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210063512.7A Active CN114452284B (en) | 2022-01-20 | 2022-01-20 | Application of STING inhibitor in preparation of medicine for treating conjunctival scarring of filter |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114452284B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1799540A (en) * | 2005-11-16 | 2006-07-12 | 陈凤华 | Use of okadaic acid in preparation of medicine for resisting glaucoma operation scar |
CN102695511A (en) * | 2009-04-17 | 2012-09-26 | 舒玛健康系统有限责任公司 | Use of transforming growth factor-Beta receptor inhibitors to suppress ocular scarring |
-
2022
- 2022-01-20 CN CN202210063512.7A patent/CN114452284B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1799540A (en) * | 2005-11-16 | 2006-07-12 | 陈凤华 | Use of okadaic acid in preparation of medicine for resisting glaucoma operation scar |
CN102695511A (en) * | 2009-04-17 | 2012-09-26 | 舒玛健康系统有限责任公司 | Use of transforming growth factor-Beta receptor inhibitors to suppress ocular scarring |
Non-Patent Citations (1)
Title |
---|
抗瘢痕形成药物在青光眼滤过术中的应用进展;张典元等;《中国中医眼科杂志》;第17卷(第3期);第177-180页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114452284A (en) | 2022-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11730716B2 (en) | Compounds for treating ophthalmic diseases and disorders | |
AU2019321429B2 (en) | Multi-kinase inhibitors of VEGF and TGF beta and uses thereof | |
EP3808352A1 (en) | Use of salidroside and derivative thereof in preparation of inhibitor medicament for diseases of ophthalmic fibrosis caused by abnormalities of extracellular matrix proteins | |
MX2011001455A (en) | Ophthalmic pharmaceutical compositions comprising sorafenib for the treatment of neoangiogenic pathologies of the eye. | |
Sharif et al. | FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma | |
Pitha et al. | Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP–Glaucoma | |
Park et al. | Effect of lovastatin on wound-healing modulation after glaucoma filtration surgery in a rabbit model | |
US9155790B2 (en) | Methods and compositions for modulating ocular damage | |
JP7542799B2 (en) | Composition for inhibiting ocular tissue fibrosis | |
EA035966B1 (en) | Use of a pharmaceutical composition for topical application in treating lacrimal system and anterior segment of the eye disorders | |
CN114452284B (en) | Application of STING inhibitor in preparation of medicine for treating conjunctival scarring of filter | |
CN102258518A (en) | Application of huperzine A to preparation of medicament for treating glaucoma and/or ischemia-induced optic nerve damage | |
Spaide et al. | Cystoid macular edema after cataract surgery | |
CA2442296C (en) | Therapeutic agents for retinochoroidal disorders comprising steroids as active ingredients | |
JP2024150780A (en) | Composition for inhibiting ocular tissue fibrosis | |
Bleau et al. | Managing intraocular pressure: Innovation in glaucoma management | |
CN116492462B (en) | Application of PAD4 inhibitor in preventing and treating immune rejection after cornea transplantation | |
RU2177801C1 (en) | Agent inhibiting angiogenesis in visual organ disease | |
US20220249432A1 (en) | Baicalein analogs for use in neuroprotection and regulation of immune reactivity | |
US20220339148A1 (en) | Multi-kinase inhibitors of vegf and tgf beta and uses thereof | |
JP3530542B2 (en) | Argatroban formulation for ophthalmology | |
CN117224546A (en) | Application of CZ415 in preparation of ocular hypotensive drugs | |
KR101869741B1 (en) | Pharmaceutical Composition for Preventing or Treating Vascular Permeability Disease Comprising Masitinib or Pharmaceutically Acceptable Salts thereof as an Active Ingredient | |
CN114828841A (en) | Use of valproic acid for reducing post-operative scarring after glaucoma surgery | |
EP2916844A1 (en) | Methods for treating eye disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |